Bristol-Myers Squibb Co. will announce new data on its approved and investigational oncology compounds at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) from June 1-5. The data further characterize the company’s cancer immunotherapies, including YERVOY (ipilimumab) in metastatic melanoma, anti-PD-1 (BMS-936558) and elotuzumab, and support the potential role of immuno-oncology in the treatment of a range of cancers.
New data on YERVOY, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody for the treatment of metastatic melanoma, will be presented in 27 abstracts. Safety and efficacy data for YERVOY in 830 U.S. patients with metastatic melanoma, including three-year survival results, will be presented along with safety results in patients with a minimum of two-years of survival in the first-line 024 Phase 3 study in combination with DTIC, and data on YERVOY in combination with existing and investigational treatments for melanoma.
Clinical data on the investigational cancer immunotherapies anti-PD-1 and anti-PD-L1 (BMS-936559) in advanced non-small-cell lung cancer, metastatic melanoma and renal cell cancer will be featured in five oral presentations.
Bristol-Myers Squibb and its partner, Abbott, will present updated Phase 2 results on the investigational cancer immunotherapy elotuzumab, which is in Phase 3 development for the treatment of multiple myeloma. Elotuzumab is a humanized monoclonal antibody specifically targeted against CS1, a cell-surface glycoprotein that is highly and uniformly expressed on multiple myeloma cells. Updated results evaluating the safety and efficacy of elotuzumab plus lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma will be presented.
Separately, the company and its partner, Otsuka Pharmaceutical Co., Ltd., will present three-year follow up data from the Phase 3 head-to-head DASISION trial, evaluating SPRYCEL (dasatinib) versus Gleevec* (imatinib mesylate) in the treatment of patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic-phase. Long-term follow up data (6 years) from the Phase 3 study (-034) that evaluated the safety and efficacy of SPRYCEL in the treatment of Ph+ CML patients with resistance or intolerance to Gleevec will also be presented.
ERBITUX (cetuximab) data in abstracts that span a wide range of investigational uses in solid tumors such as colorectal and head and neck will be presented along with additional analysis from the CRYSTAL study of ERBITUX in the first-line treatment of metastatic colorectal cancer (mCRC). CRYSTAL served as the basis for the first-line mCRC supplement biologics application for ERBITUX. The Company expects the FDA to take action on the filing in the second half of this year. Bristol-Myers Squibb is developing ERBITUX in partnership with Eli Lilly and Company.
Release Date: May 16, 2012
Source: Bristol-Meyers Squibb
